Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ).
Zylox-Tonbridge Medical Technology Co., Ltd. reported a significant increase in revenue and profit for the first half of 2025, with a 31.7% rise in revenue compared to the same period in 2024. This growth was driven by high sales in both neurovascular and peripheral vascular interventional devices, with notable contributions from established products and the successful launch of new products across hospitals nationwide.
The most recent analyst rating on (HK:2190) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a company based in China that specializes in the development, production, and commercialization of medical devices, particularly focusing on neurovascular and peripheral vascular interventional products.
Average Trading Volume: 649,977
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.41B
For an in-depth examination of 2190 stock, go to TipRanks’ Overview page.